Randomized Trial for Non-small Cell Lung Cancer after Progression on EGFR TKI

Trial ID:
IRB-22-7988
Michael P. Kosty, M.D.
This study will compare the safety and effectiveness of patritumab deruxtecan to standard of care platinum-based chemotherapy. Patients will be randomized (like the flip of a coin) to receive either patritumab deruxtecan or platinum-based chemotherapy and will know which treatment they are receiving. Patritumab deruxtecan is an investigational drug being used only in research.

Inclusion Criteria

Patients must:

  • Have EGFR-mutated Non-small Cell Lung Cancer.
    Have disease progression while receiving a third-generation EGFR TKI (such as Tagrisso).
    Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
    Be willing to provide tumor tissue by either a new tumor biopsy or from a previous biopsy performed on or after treatment with EGFR TKI.

Exclusion Criteria

Patients must not:

  • Have received other prior systemic cancer therapies (including chemotherapy, immunotherapy, etc) since being diagnosed with metastatic or locally advanced disease.
    Have clinically active brain metastases or spinal cord compression.
    Have a history of interstitial lung disease, severe respiratory compromise, or significant cardiovascular disease.
    Be pregnant or nursing.

Additional Info

All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion) and Scripps MD Anderson Prebys Cancer Center.

Participation in the study will last for up to 49 months.

Search for NCT05338970 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org